Company news

Cartesian Therapeutics, Inc. news in 2026

Cartesian Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cartesian Therapeutics Announces New Employment Inducement Grant

November 3, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

October 2, 2026

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

September 29, 2026

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

June 8, 2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

May 26, 2026

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 12, 2026

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

April 30, 2026

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

March 9, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

January 9, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

January 6, 2026

Decks in 2026